Anika Therapeutics up as pain relief drug meets main goal in late-stage study

Anika Therapeutics

01/11/2022 16:56

** Anika Therapeutics Inc's shares  ANIK.O  rise 2.5% to
$29.12
    ** Drugmaker says its experimental drug to treat joint pain
after treatment meets primary main goal in late-stage study
 urn:newsml:reuters.com:*:nGNX2jn1md
    ** The drug, Cingal, demonstrated superiority over existing
steroid treatment, triamcinolone hexacetonide, at 26 weeks
    ** Co plans to meet with FDA to discuss next steps for U.S.
regulatory approval
    ** Including session gains, stock down ~18% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))